Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

26.58
+2.098.53%
Post-market: 26.45-0.1300-0.49%19:47 EDT
Volume:1.73M
Turnover:45.46M
Market Cap:3.32B
PE:123.39
High:26.97
Open:24.50
Low:24.30
Close:24.49
52wk High:31.77
52wk Low:19.30
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.79
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:15.07
PE(LYR):-209.52

Loading ...

Arcutis Biotherapeutics presents data across Zoryve portfolio

TIPRANKS
·
Yesterday

Arcutis Says Phase 2 Trial Shows Zoryve Cream 0.05% Clears Atopic Dermatitis in Infants Ages 3 to Under 24 Months

Reuters
·
Yesterday

Arcutis Grants 62,500 RSUs to Six New Hires Under 2022 Inducement Plan

Reuters
·
Oct 03

Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Oct 03

Arcutis EVP, Chief Legal Officer Masaru Matsuda Disposes of 3,674 Common Shares for $91,753.31

Reuters
·
Sep 19

Arcutis Biotherapeutics falls -5.1%

TIPRANKS
·
Sep 18

Arcutis EVP, Chief Legal Officer Masaru Matsuda Sells 9,989 Shares for $249,861

Reuters
·
Sep 11

S&P 500 to Add Bloom Energy, Illumina and Everpure in September Rebalance

Tiger Newspress
·
Sep 05

Arcutis Biotherapeutics Grants 57,000 RSUs to 11 New Hires Under Inducement Plan

Reuters
·
Sep 05

Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Sep 05

Arcutis Director Terrie Curran Disposes of Common Shares Worth $279,129.66

Reuters
·
Aug 29

Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable?

Simply Wall St.
·
Aug 27

Insider Move at Arcutis Biotherapeutics Sends Strong Signal to Investors

TIPRANKS
·
Aug 25

Arcutis Biotherapeutics Director Terrie Curran Disposes of 1,072 Common Shares Worth $27,927.31

Reuters
·
Aug 25

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Top Arcutis Executive Makes Notable Move With Latest Stock Sale

TIPRANKS
·
Aug 22

Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis

TIPRANKS
·
Aug 22

Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis

MT Newswires Live
·
Aug 21

Arcutis Canada: Przoryve Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
Aug 21

Arcutis Biotherapeutics Director Howard G. Welgus Sells 4,730 Common Shares for $123,835.71

Reuters
·
Aug 20